Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node RadiationMonika L. Metzger, Matthew J. Krasin, Michael P. Link et al.|Journal of Clinical Oncology|2021Cited by 59
Multidisciplinary treatment of primary intracranial yolk sac tumorZhenning Xu, Ming Zhang, Chen Li et al.|Medicine|2021Cited by 5
Excellent Outcome for Pediatric Patients with High Risk Hodgkin Lymphoma with Brentuximab Vedotin and Risk Adapted Residual Node RadiationMonika L. Metzger, Matthew J. Krasin, Michael P. Link et al.|SSRN Electronic Journal|2020Cited by 0